SLFN11 and small cell lung carcinoma: As with the cell lines, we also observed a bimodal distribution of SLFN11 in publically available mRNA data from 70 early-stage, treatment-naïve SCLC patient tumors (BI=1.46; Supplementary Figure 4A) [6], with 74% of tumors classified as SLFN11-high based on their BI.